Evaluation of Hepatic Pharmacokinetics for Grazoprevir (MK-5172) in Participants With Chronic Hepatitis C (MK-5172-022)

Exclusion Criteria

• •History of any of the following: stroke, chronic seizures, major neurological disorders, gastric bypass surgery or bowel resection.
• •No viral response to prior interferon based therapy.
• •Prior treatment for HCV with an NS3/4A protease inhibitor.
• •History of either clinically significant, uncontrolled endocrine, gastrointestinal, cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities/diseases.
• •History of neoplastic or myeloproliferative disease.
• •Has any of the following : cirrhosis, decompensated liver disease, or other advanced liver disease, hepatocellular carcinoma, infection with human immunodeficiency virus (HIV), or hepatitis B.
• •Evidence of high grade bridging fibrosis from prior liver biopsy or chronic hepatitis not caused by HCV.
• •History of illicit drug use or alcohol abuse.
• •Had surgery, donated at least one unit of blood, or participated in any other investigational study within 4 weeks prior to screening visit.
• •History of multiple and/or severe allergies.